Why is Intellia Therapeutics (NTLA) a Battleground Stock with 38% Short Interest

Related Articles

Why is Avidity Biosciences (RNA) a Battleground Stock with Massive Short Interest

7 months ago

What Does High Short Interest Really Mean for a Stock

7 months ago

Why is CleanSpark Attracting Such High Short Interest

8 months ago

Why is Kaixin Holdings (KXIN) Facing Such Extreme Short Interest

7 months ago

Category

You may also like

Stock News•2 weeks ago

Top 10 Powder Keg Stocks Where Short Sellers Are Sitting on a Fuse

Ten stocks each carry short interest above 38% of float as of Oct. 12, per Benzinga Pro screener data, with market caps over $2B and average daily volume above 1M shares. The heavy short positioning s...

BEAM

Share

Stock News•2 weeks ago

Intellia Therapeutics (NTLA) Soars 7.6%: Is Further Upside Left in the Stock?

Intellia Therapeutics (NTLA) shares jumped 7.6% on above-average volume, but recent earnings estimate revisions suggest limited further upside.

NTLA

Share

Stock News•3 weeks ago

Inhibrx's Insider Buying Adds Fuel to a High-Short-Interest Biotech Setup

Inhibrx Biosciences CEO bought over $3.6M of INBX shares after a clinical outperformance selloff, with ~28% of float short and an FDA approval date pending. The stock closed at $97.93, down 2.15% on 1...

INBX

Share